Phase I/II Trial of Autologous Peripheral Blood Progenitor Cell Transplantation With VELCADE Maintenance as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 17 Mar 2016
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 03 Aug 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 17 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Feb 2011 Planned End Date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.